Products for Research Use Only
RegisterLogin

Tanimilast

CAT: 0804-HY-19929-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19929-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tanimilast (CHF-6001) is an orally active and selective phosphodiesterase 4 inhibitor (IC50=0.026 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration. Tanimilast increases cellular cAMP levels, and inhibits NF-κB signaling pathway. Tanimilast is used for the research of obstructive lung diseases[1][2].
CAS Number
1239278-59-1
Product Name Alternative
CHF-6001
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
CCR; CXCR; Interleukin Related; NF-κB; Phosphodiesterase (PDE) ; TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tanimilast.html
Concentration
10mM
Purity
99.71
Solubility
DMSO : 200 mg/mL (ultrasonic; warming)
Smiles
O=C(O[C@H](C1=CC=C(OC(F)F)C(OCC2CC2)=C1)CC3=C(Cl)C=[N+]([O-])C=C3Cl)C4=CC=C(NS(=O)(C)=O)C(OCC5CC5)=C4
Molecular Formula
C30H30Cl2F2N2O8S
Molecular Weight
687.54
Precautions
H302, H315, H319
References & Citations
[1]Moretto N, et al., CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J Pharmacol Exp Ther. 2015 Mar;352 (3) :559-67.|[2]Gianello V, et al., The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells. Biochem Pharmacol. 2019 May;163:371-380.|[3]Stellari FF, et al., CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice. Front Pharmacol. 2019 Nov 12;10:1337.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PDE4

Alternative Products

CatalogName
GTR19189793-01Tanimilast

Popular Products